Skip to main content
. Author manuscript; available in PMC: 2023 Jan 28.
Published in final edited form as: Haemophilia. 2019 Jul;25(4):581–589. doi: 10.1111/hae.13717

FIGURE 1.

FIGURE 1

Clinical Trial Concept 1: Inhibitor Prevention: Emicizumab plus FVIII vs FVIII Alone in PUPs Trial. Previously untreated patients (PUPs) with severe haemophilia A are randomized to receive weekly emizicumab plus FVIII vs weekly FVIII alone and are followed for inhibitor formation >5.0 BU at prespecified time-points for 48 wk